Senolytic stack (quercetin + dasatinib protocols)

Tier 3 — weak evidence · Senescent cell clearance · Experimental · Intermittent

Intermittent high-dose protocols combining quercetin (and increasingly fisetin) with — in research settings — dasatinib (a prescription tyrosine-kinase inhibitor) target senescent cells (the "zombie cells" implicated in aging-related decline). Mayo Clinic pilot trials in idiopathic pulmonary fibrosis and diabetic kidney disease are encouraging. Self-administering dasatinib is not appropriate; the supplement-only versions (quercetin + fisetin) lack outcome-trial data. Capped at T3 until human longevity endpoints are established.

Dose: Research protocols use quercetin 1,000 mg + fisetin 1,000 mg daily for 2 days/month; dasatinib protocols are clinician-only